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Conclusions: Choice of CNI does not influence death-censored graft loss
and mortality in recipients aged !60 years. Selection of CNI in this popula-
tion should be influenced by the patient’s individual susceptibility to the
reported secondary outcomes.
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Background: Mesenchymal stromal cells (MSCs) have particular properties
that can be of interest in organ transplantation, including expansion of regu-
latory T cells (Tregs), a key factor in graft tolerance induction. The immuno-
suppression to be associated with MSCs has not yet been defined.
Additionally, the impact of the association of everolimus with MSCs on Treg
expansion and on induction of liver graft tolerance has never been studied.
The aim of this study was to evaluate the effects of MSCs combined, or
not, with everolimus, on Treg expansion and in a model of liver transplanta-
tion (LT) rejection in the rat.
Methods: Firstly, Lewis rats received intravenous MSCs at D9 with/without
subcutaneous everolimus from D0 to D14. Analysis of circulating Tregs was
performed at D0, D14 and D28. Secondly, 48 h after LT with a Dark
Agouti rat liver, 30 Lewis rats were randomized in 3 groups: everolimus
(subcutaneous for 14 days), MSCs (intravenous injection at D2 and D9), or
both everolimus and MSCs. Rejection of the liver graft was assessed by
liver tests, histology and survival.
Results: Individually, MSC infusion and everolimus promoted Treg expan-
sion in rats, and everolimus had no negative impact on Treg expansion
when combined with MSCs. However, in the LT model, injections of MSCs
2 and 9 days following LT were not effective at preventing acute rejection,
and the combination of MSCs with everolimus failed to show any synergistic
effect when compared to everolimus alone.
Conclusion: Everolimus may be used in association with MSCs. However,
in our model of LT in the rat, post-transplant MSC injections did not prevent
acute rejection, and the association of MSCs with everolimus did not show
any synergistic effect.
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Background: Granzyme B (GZMB)-expressing B cells have been shown to
be an important regulatory B cell subset in humans. However, it is unclear
which subpopulations of B cells express GZMB under normal conditions
and which protocols effectively induce ex vivo expansion of GZMB+ B cells.
Methods: Fresh human PBMCs were isolated from healthy blood donors by
Ficoll gradient centrifugation and phenotyped by flow cytometry. B cells and
CD4+CD25! effector T cells were negatively selected using magnetic
beads. GZMB+ B cells were expanded using a cytokine cocktail and cocul-
tured with effector T cells. The phenotype and the mechanisms underlying
the suppressive capacity of expanded GZMB+ B cells were studied.
Results: We found that in the peripheral blood of normal individuals, plas-
mablasts were the major B cell subpopulation that expressed GZMB. However,
when using an in vitro plasmablast differentiation protocol, we obtained only
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